TRI Groundbreaking Research

Researchers at the AdventHealth Translational Research Institute are on the front lines of the battle against diabetes and other chronic diseases. As part of a dedicated team, they tirelessly work to improve the lives of patients by spearheading innovative clinical trials and research. Their groundbreaking work has been recognized internationally, with their findings featured in numerous prestigious scientific and health journals in the past few months.

Semaglutide (the active ingredient in the weight loss drug Ozempic) showed promise in reducing heart failure events in patients with HFpEF. A study of over 22,000 participants found that for people with a type of heart failure called HFpEF, a medication called semaglutide helped reduce the chances of experiencing serious heart problems or needing to go to the hospital for heart failure. While its effect on heart-related death was less pronounced, semaglutide could be a valuable addition to treatment options for HFpEF.

For more information: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01643-X/abstract

Semaglutide, a drug used to treat Type 2 diabetes, has been shown to reduce the risk of heart failure and cardiovascular death in people with both Type 2 diabetes and Chronic Kidney Disease. This was demonstrated in a large clinical trial called FLOW. Participants were randomly assigned to receive either semaglutide or a placebo. Those taking semaglutide had a significantly lower risk of experiencing heart failure events or dying from cardiovascular causes compared to those taking the placebo. These findings suggest that semaglutide could be a valuable treatment option for people with these conditions.

For more information: https://pubmed.ncbi.nlm.nih.gov/39217553/#:~:text=Conclusions%3A%20Semaglutide%20substantially%20reduced%20the,regardless%20of%20history%20of%20HF.

Semaglutide, a medication for Type 2 diabetes, has been shown to reduce the risk of heart attacks, strokes, and death in people with both diabetes and kidney problems. This study analyzed the data from the FLOW trial to examine the relationship between the severity of chronic kidney disease and the benefits of semaglutide treatment in patients with Type 2 diabetes and heart failure. The researchers compared the outcomes of patients with varying degrees of kidney dysfunction to identify if semaglutide's effectiveness was influenced by the stage of kidney disease. The study followed participants for over three years, and the benefits of semaglutide were seen regardless of how severe their kidney disease was.

For more information, https://pubmed.ncbi.nlm.nih.gov/39211948/

GLP-1 receptor agonists offer consistent cardiovascular and kidney benefits for people with type 2 diabetes, regardless of whether they're also taking SGLT2 inhibitors. This study analyzed the effects of GLP-1 agonists on heart health and kidney function in people with Type 2 diabetes. It found that these medications reduced the risk of heart attacks, strokes, and heart failure, as well as improved kidney health, regardless of whether the patients were already taking SGLT2 inhibitors.

For more information, https://pubmed.ncbi.nlm.nih.gov/39210781/

Semaglutide with or without SGLT2 Inhibitor in Type 2 Diabetes and Chronic Kidney Disease. The study looked at people with Type 2 diabetes and Chronic Kidney Disease who are at high risk for kidney failure and heart problems. They found that a medication called semaglutide helped lower this risk, regardless of whether the patient was already taking another medication for their kidneys. The benefit for heart health and overall death rate was also similar. This suggests that semaglutide could be a valuable treatment option for this group of people.

For more information, https://research.regionh.dk/en/publications/effects-of-semaglutide-with-and-without-concomitant-sglt2-inhibit

Newer Anti-Hyperglycemic Agents in Older Adults. This study examined the cardiovascular safety of three types of diabetes medications (DPP-4i, GLP-1RA, and SGLT-2i) in different age groups. By analyzing large clinical trials, researchers found that SGLT-2i and GLP-1RA medications reduced the risk of heart attacks, strokes, and death in people with Type 2 diabetes, regardless of their age. However, DPP-4i medications did not show any significant benefit in reducing cardiovascular risk. Overall, these findings suggest that newer diabetes medications are generally safe for people of all ages.

For more information, https://pubmed.ncbi.nlm.nih.gov/38870731/

Semaglutide in Chronic Kidney Disease. This study investigated the potential renoprotective effects of semaglutide in patients with Type 2 diabetes and chronic kidney disease. Participants were randomized to receive semaglutide or a placebo, and their kidney function was monitored over time. The researchers aimed to determine if semaglutide could slow the progression of kidney disease and improve patient outcomes.

For more information, https://pubmed.ncbi.nlm.nih.gov/38785209/

DCRM 2.0: Multispecialty Practice Recommendations. DCRM 2.0 is a comprehensive set of guidelines developed by a panel of experts to provide evidence-based recommendations for the management of diabetes, cardiorenal, and metabolic diseases. The guidelines offer practical guidance for healthcare providers, covering various aspects of patient care, including diagnosis, treatment options, monitoring, and prevention of complications.

For more information, https://pubmed.ncbi.nlm.nih.gov/38852020/